Hengrui Oncology is turning China’s health‑care goals into reality with a string of breakthrough cancer medicines. In breast cancer, its trio of drugs—Pyrotinib (Airenii®), dalpiciclib (Airikang®) and the next‑generation HER2‑ADC recotumumab (Airvida®)—have reshaped treatment guidelines and pushed median progression‑free survival past 30 months for several sub‑types. For liver cancer, the “dual AI” combo of camrelizumab and apatinib delivered a record‑breaking 23.8‑month median overall survival in first‑line patients, while early‑stage trials showed big gains in event‑free survival after surgery. In gastric cancer, Hengrui launched the world’s first PD‑L1/TGF‑β bispecific antibody, Aizeli®, offering a brand‑new option for advanced disease. The company also backs patients with supportive‑care products that curb nausea, neutropenia and low platelet counts, preserving quality of life during treatment. Beyond the lab, Hengrui’s drugs have raced into China’s national medical‑insurance catalog—often within months of approval—making cutting‑edge therapies affordable for millions. The firm has struck more than a dozen out‑licensing deals worth over $27 billion and is expanding its R&D footprint across Asia, Europe, North America and Australia. Aligning with the 15th Five‑Year Plan, Hengrui vows to keep turning unmet clinical needs into global‑impact innovations, ensuring Chinese breakthroughs benefit patients worldwide.
Read more